Not provided
Not provided
Not provided
Not provided
Not provided
The study was terminated prematurely on 16 May 2014 due to a safety concern.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A (Pilot Study) | No Intervention | ||
| Monotherapy (Part B) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-05175157 | Drug | PF-05175157 will be administered at 200 mg twice a day for 43 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glucose Infusion Rates (GIR) in Part A | GIR obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. Assessment of whole body insulin sensitivity was performed during the steady states of the low insulin infusion rate (ie, Step 1) and during the steady state of the high insulin infusion rate (ie, Step 2). These indices were called GIR1 and GIR2, respectively. | 1 day |
| Endogenous Gucose Production (EGP) in Part A | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2). Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. EGP was measured under basal conditions; then during the low dose insulin infusion EGP was partially suppressed (hepatic insulin sensitivity), while during the high dose insulin infusion, EGP was almost completely suppressed and peripheral glucose uptake was maximally stimulated (peripheral insulin sensitivity). | 1 day |
| [6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A | [6,6-2H2] PGE was the molar fraction of labeled glucose measured in plasma. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. | 1 day |
| Rate of Appearance of Glucose (Ra) in Part A | Rate of appearance of glucose (Ra) in fasting state and during insulin infusions (Step 1 and Step 2). |
| Measure | Description | Time Frame |
|---|---|---|
| GIR in Part B in Placebo Group | Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. | 6 weeks |
| GIR in Part B in PF-05175157 200 mg BID Group |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subjects with history of dry eye, known ocular or systemic disease that affect the sclera or cornea.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Profil Institute for Clinical Research, Inc. | Chula Vista | California | 91911 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Participants in Part A | Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual's insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min. |
| FG001 | Placebo - Part B | Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. |
| FG002 | PF-05175157 200 mg Twice a Day - Part B | Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A |
| |||||||||||||
| Part B |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants in Part A | Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual's insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Glucose Infusion Rates (GIR) in Part A | GIR obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. Assessment of whole body insulin sensitivity was performed during the steady states of the low insulin infusion rate (ie, Step 1) and during the steady state of the high insulin infusion rate (ie, Step 2). These indices were called GIR1 and GIR2, respectively. | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | Posted | Mean | 90% Confidence Interval | mg/min | 1 day |
|
Baseline up to follow-up (up to approximately 3 days after the last clamp procedure in Part A and up to approximately 10 to 14 days after the last study drug administration in Part B)
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | All Participants in Part A | Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual's insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 17.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lacrimation increased | Eye disorders | MedDRA 17.0 | Non-systematic Assessment |
Part B of the study was terminated due to the safety issue. Due to the low number of participants who completed the study, there are no conclusions for PK or PD in Part B. The prioritization of Part A endpoints was done by inputs from team.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClnicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days. |
|
| 1 day |
| Whole-body Glucose Uptake in Part A | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | 1 day |
| Whole-body Glucose Uptake in Part B in Placebo Group | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | 6 weeks |
| Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | 6 weeks |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B | An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | Baseline to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
| Number of Participants With Laboratory Test Abnormalities in Part B | Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone [FSH], urine drug screen, lipid profile and very-low-density lipoproteins [VLDL], hemoglobin A1c [HbA1c], C-peptide, thyroid-stimulating hormone [TSH], Hepatitis B and C, human immunodeficiency virus [HIV], triglycerides, urine creatinine). | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
| Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B | Criteria for potentially clinical important (PCI) change in vital signs included: sitting systolic blood pressure (SBP) of less than (<) 90 millimeters of mercury (mm Hg) or change in sitting SBP of greater or equal to (>=)30 mm Hg, sitting diastolic blood pressure (DBP) of <50 mm Hg or change in sitting DBP of >=20 mm Hg, sitting pulse rate of <40 or greater than (>) 120 beats per minute (bpm). | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
| Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B | Criteria for PCI changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) >=300 milliseconds (msec) and increase of >=25% from baseline when baseline >200 msec or increase of >=50% when baseline less than or equal to (<=) 200 msec; the time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS interval) >=140 msec and increase of >=50% from baseline; the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT), corrected for heart rate (QTc) using the Fridericia formula (QTcF) of 450 to < 480 msec and >=480 msec, or an increase from baseline of 30 to <60 msec or >=60 msec. | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. |
| 6 weeks |
| EGP in Part B in Placebo Group | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2) | 6 weeks |
| EGP in Part B in PF-05175157 200 mg BID Group | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2) | 6 weeks |
| Ra in Part B in Placebo Group | Ra in fasting state and during insulin infusions (Step 1 and Step 2). | 6 weeks |
| Ra in Part B in PF-05175157 200 mg BID Group | Ra in fasting state and during insulin infusions (Step 1 and Step 2). | 6 weeks |
| NOT COMPLETED |
|
|
| BG001 | Placebo - Part B | Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. |
| BG002 | PF-05175157 200 mg Twice a Day - Part B | Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. |
| BG003 | Total | Total of all reporting groups |
| Years |
|
| Sex/Gender, Customized | Number | Participants |
|
Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual's insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.
|
|
| Primary | Endogenous Gucose Production (EGP) in Part A | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2). Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. EGP was measured under basal conditions; then during the low dose insulin infusion EGP was partially suppressed (hepatic insulin sensitivity), while during the high dose insulin infusion, EGP was almost completely suppressed and peripheral glucose uptake was maximally stimulated (peripheral insulin sensitivity). | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | Posted | Median | Full Range | mg/kilogram (kg) body weight (BW)/min | 1 day |
|
|
|
| Primary | [6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A | [6,6-2H2] PGE was the molar fraction of labeled glucose measured in plasma. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp | Posted | Mean | 90% Confidence Interval | percentage enrichment of plasma glucose | 1 day |
|
|
|
| Primary | Rate of Appearance of Glucose (Ra) in Part A | Rate of appearance of glucose (Ra) in fasting state and during insulin infusions (Step 1 and Step 2). | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp. | Posted | Mean | Full Range | mg/kg BW/min | 1 day |
|
|
|
| Primary | Whole-body Glucose Uptake in Part A | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | All participants randomized and who had at least one euglycemic hyperinsulinemic clamp. | Posted | Mean | 90% Confidence Interval | mg/kg BW/min | 1 day |
|
|
|
| Primary | Whole-body Glucose Uptake in Part B in Placebo Group | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/kg BW/min | 6 weeks |
|
|
|
| Primary | Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group | Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/kg BW/min | 6 weeks |
|
|
|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B | An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | All participants who were admitted to the clinical research unit (CRU) on Day -5 | Posted | Number | Participants | Baseline to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
|
|
|
| Primary | Number of Participants With Laboratory Test Abnormalities in Part B | Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone [FSH], urine drug screen, lipid profile and very-low-density lipoproteins [VLDL], hemoglobin A1c [HbA1c], C-peptide, thyroid-stimulating hormone [TSH], Hepatitis B and C, human immunodeficiency virus [HIV], triglycerides, urine creatinine). | All participants who were admitted to the Clinical Research Unit (CRU) on Day -5 | Posted | Number | Participants | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
|
|
|
| Primary | Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B | Criteria for potentially clinical important (PCI) change in vital signs included: sitting systolic blood pressure (SBP) of less than (<) 90 millimeters of mercury (mm Hg) or change in sitting SBP of greater or equal to (>=)30 mm Hg, sitting diastolic blood pressure (DBP) of <50 mm Hg or change in sitting DBP of >=20 mm Hg, sitting pulse rate of <40 or greater than (>) 120 beats per minute (bpm). | All participants who were admitted to the CRU on Day -5 | Posted | Number | Participants | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
|
|
|
| Primary | Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B | Criteria for PCI changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) >=300 milliseconds (msec) and increase of >=25% from baseline when baseline >200 msec or increase of >=50% when baseline less than or equal to (<=) 200 msec; the time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS interval) >=140 msec and increase of >=50% from baseline; the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT), corrected for heart rate (QTc) using the Fridericia formula (QTcF) of 450 to < 480 msec and >=480 msec, or an increase from baseline of 30 to <60 msec or >=60 msec. | All participants who were admitted to the CRU on Day -5. | Posted | Number | Participants | Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration) |
|
|
|
| Secondary | GIR in Part B in Placebo Group | Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/min | 6 weeks |
|
|
|
| Secondary | GIR in Part B in PF-05175157 200 mg BID Group | Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/min | 6 weeks |
|
|
|
| Secondary | EGP in Part B in Placebo Group | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2) | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Median | Full Range | mg/kg fat free mass (FFM)/min | 6 weeks |
|
|
|
| Secondary | EGP in Part B in PF-05175157 200 mg BID Group | EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2) | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Median | Full Range | mg/kg fat free mass (FFM)/min | 6 weeks |
|
|
|
| Secondary | Ra in Part B in Placebo Group | Ra in fasting state and during insulin infusions (Step 1 and Step 2). | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/kg BW/min | 6 weeks |
|
|
|
| Secondary | Ra in Part B in PF-05175157 200 mg BID Group | Ra in fasting state and during insulin infusions (Step 1 and Step 2). | Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B. | Posted | Mean | Full Range | mg/kg BW/min | 6 weeks |
|
|
|
| 0 |
| 6 |
| 0 |
| 6 |
| EG001 | PF-05175157 200 mg Twice a Day - Part B | Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. | 1 | 7 | 5 | 7 |
| EG002 | Placebo - Part B | Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks. | 0 | 6 | 1 | 6 |
| Constipation | Gastrointestinal disorders | MedDRA 17.0 | Non-systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 17.0 | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 17.0 | Non-systematic Assessment |
|
| Blister | Skin and subcutaneous tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 17.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D004700 | Endocrine System Diseases |
| Title | Measurements |
|---|---|
|
| Clamp 2 EGP0 |
|
| Clamp 2 EGP1 |
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Step 2 Value 4 |
|
| Step 2 Value 5 |
|
| Step 2 Value 6 |
|
| Step 2 Value 7 |
|
| Step 2 Value 8 |
|
| Title | Measurements |
|---|---|
|
| Step 2 Value 4 |
|
| Step 2 Value 5 |
|
| Step 2 Value 6 |
|
| Step 2 Value 7 |
|
| Step 2 Value 8 |
|
| Step 2 Value 9 |
|
| Step 2 Value 10 |
|
| Participants discontinued due to AEs |
|
| Pulse Rate <40 bpm |
|
| Pulse Rate >120 bpm |
|
| SBP maximum increase from baseline >=30 mm Hg |
|
| DBP maximum increase from baseline >=20 mm Hg |
|
| SBP maximum decrease from baseline >=30 mm Hg |
|
| DBP maximum decrease from baseline >=20 mm Hg |
|
| Title | Measurements |
|---|---|
|
| GIR1 Value 4 |
|
| GIR1 Value 5 |
|
| GIR1 Value 6 |
|
| GIR1 Value 7 |
|
| GIR1 Value 8 |
|
| GIR2 Value 1 |
|
| GIR2 Value 2 |
|
| GIR2 Value 3 |
|
| GIR2 Value 4 |
|
| GIR2 Value 5 |
|
| GIR2 Value 6 |
|
| GIR2 Value 7 |
|
| GIR2 Value 8 |
|
| Title | Measurements |
|---|---|
|
| GIR1 Value 4 |
|
| GIR1 Value 5 |
|
| GIR1 Value 6 |
|
| GIR1 Value 7 |
|
| GIR1 Value 8 |
|
| GIR1 Value 9 |
|
| GIR1 Value 10 |
|
| GIR2 Value 1 |
|
| GIR2 Value 2 |
|
| GIR2 Value 3 |
|
| GIR2 Value 4 |
|
| GIR2 Value 5 |
|
| GIR2 Value 6 |
|
| GIR2 Value 7 |
|
| GIR2 Value 8 |
|
| GIR2 Value 9 |
|
| GIR2 Value 10 |
|
| Title | Measurements |
|---|---|
|
| EGP0 Value 4 |
|
| EGP0 Value 5 |
|
| EGP0 Value 6 |
|
| EGP0 Value 7 |
|
| EGP0 Value 8 |
|
| EGP1 Value 1 |
|
| EGP1 Value 2 |
|
| EGP1 Value 3 |
|
| EGP1 Value 4 |
|
| EGP1 Value 5 |
|
| EGP1 Value 6 |
|
| EGP1 Value 7 |
|
| EGP1 Value 8 |
|
| EGP2 Value 1 |
|
| EGP2 Value 2 |
|
| EGP2 Value 3 |
|
| EGP2 Value 4 |
|
| EGP2 Value 5 |
|
| EGP2 Value 6 |
|
| EGP2 Value 7 |
|
| EGP2 Value 8 |
|
| Title | Measurements |
|---|---|
|
| EGP0 Value 4 |
|
| EGP0 Value 5 |
|
| EGP0 Value 6 |
|
| EGP0 Value 7 |
|
| EGP0 Value 8 |
|
| EGP0 Value 9 |
|
| EGP0 Value 10 |
|
| EGP1 Value 1 |
|
| EGP1 Value 2 |
|
| EGP1 Value 3 |
|
| EGP1 Value 4 |
|
| EGP1 Value 5 |
|
| EGP1 Value 6 |
|
| EGP1 Value 7 |
|
| EGP1 Value 8 |
|
| EGP1 Value 9 |
|
| EGP1 Value 10 |
|
| EGP2 Value 1 |
|
| EGP2 Value 2 |
|
| EGP2 Value 3 |
|
| EGP2 Value 4 |
|
| EGP2 Value 5 |
|
| EGP2 Value 6 |
|
| EGP2 Value 7 |
|
| EGP2 Value 8 |
|
| EGP2 Value 9 |
|
| EGP2 Value 10 |
|
| Title | Measurements |
|---|---|
|
| Step 2 Value 4 |
|
| Step 2 Value 5 |
|
| Step 2 Value 6 |
|
| Step 2 Value 7 |
|
| Step 2 Value 8 |
|
| Title | Measurements |
|---|---|
|
| Step 2 Value 4 |
|
| Step 2 Value 5 |
|
| Step 2 Value 6 |
|
| Step 2 Value 7 |
|
| Step 2 Value 8 |
|
| Step 2 Value 9 |
|
| Step 2 Value 10 |
|